Two rapid-dose titrations of sertindole in patients with schizophrenia

Journal of Clinical Psychopharmacology

Volumn 17, Issue 5, 1997, Pages 419-422

  Sramek, John J ^a   Mack, Randall J ^b   Awni, Walid ^b   Hourani, Jameel ^a   Jhee, Stanford S ^a   Barto, Sharon ^a   Cutler, Neal R ^a,c  

^a CALIFORNIA CLINICAL TRIALS   (United States)

^b ABBOTT LABORATORIES   (United States)

^c 8500 Wilshire Blvd ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; SERTINDOLE;

ADULT; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MALE; NOSE CONGESTION; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE BLIND PROCEDURE; TACHYCARDIA; XEROSTOMIA;

ADULT; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; IMIDAZOLES; INDOLES; MALE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0030821585     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199710000-00011     Document Type: Article

References (13)

1. Skarsfeldt T, Perregaard J. Sertindole, a new neuroleptic with extreme selectivity on A10 versus A9 dopamine neurones in rat. Eur J Pharmacol 1990;182:613-4.
2. Sanchez C, Arnt J, Dragsted N, Hyttel J, Lembol HL, Meier E, Skarsfeldt T. Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound. Drug Dev Res 1991;22:239-50.
3. van Kammen DP, McEvoy JP, Targum SD, Kardatzke D, Sebree TB, Sertindole Study Group. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 1996;124;168-75.
4. Zimbroff D, Kane J, Tamminga C, Daniel D, Mack R, Wozniak P, Sebree T, Wallin B, Kashkin K. A controlled, dose-response study of sertindole and haloperidol in schizophrenia Am J Psychiatry 1997;154:782-91.
5. Wong SL, Menacherry S, Mulford D, Schmitz PJ, Locke C, Granneman GR. Pharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function. Eur J Clin Pharmacol 1997;52:223-7.
6. Coffman JA, Nasrallah HA, Lyskowski J, McCalley-Whitters M, Dunner FJ. Clinical effectiveness of oral and parenteral rapid neuroleptization. J Clin Psychiatry 1987;48:20-4.
7. Keck PE, Cohen BM, Baldessarini RJ, McElroy SL. Time course of antipsychotic effects of neuroleptic drugs. Am J Psychiatry 1989; 146:1289-92.
8. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-35.
9. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.
10. Skarsfeldt T. Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat. Eur J Pharmacol 1995;281:289-94.
11. Granneman GR, Wozniak P, Ereshefsky L, Silber C, Mack R. Population pharmacokinetics of sertindole during long-term treatment of patients with schizophrenia. Presented at the 35th meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 9-12, 1996.
12. Ereshefsky L, Watanabe MD, Tran-Johnson TK. Clozapine: an atypical antipsychotic agent. Clin Pharm 1989;8:691-709.
13. Gerlach J, Koppelhus P, Helweg E, Monrad A. Clozapine and haloperidol in a single-blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia. Acta Psychiatr Scand 1974;50:410-24.